Ibuprofen

关注我，每天 get 一个实用医学科普，避开健康误区，守护自己和家人的健康～ 半夜大脚趾突然红肿热痛，疼得睡不着，吃了止痛药好不容易压下去，没过多久又发作…… 这是很多痛风患者的真实写照。 痛风之所以难缠，是因为它既有 "尿酸高" 的根源问题，又有 "急性炎症" 的发作问题。传统治疗往往只能顾一头，效果不够理想。 2026 年，痛风治疗领域迎来了不少新进展：生物制剂从降尿酸和抗炎两条通路同时发力，口服创新药物也不断涌现。今天咱们就用大白话，把这些新疗法梳理清楚。 一、先搞清楚：痛风为什么会反复发作？ 痛风的本质是 高尿酸血症 导致尿酸盐结晶沉积在关节里，引发急性炎症反应。 打个比方：血液里的尿酸就像水里的盐，浓度太高了就会析出结晶。这些结晶像细小的碎玻璃一样扎在关节里，免疫系统发现后就会启动 "灭火" 程序，释放大量炎症因子，关节就会出现红肿热痛。 痛风反复发作的原因主要有两个： 尿酸没控制好 ：血尿酸长期居高不下，结晶不断形成和沉积 炎症没控制好 ：结晶刺激引发的炎症反应没有被有效阻断 所以，痛风管理需要 "两条腿走路"：一方面降尿酸，从源头减少结晶；另一方面控制炎症，减少急性发作。 二、传统治疗有哪些局限？ 目前痛风的传统治疗药物主要分两类： 降尿酸药 别嘌醇、非布司他 ：抑制尿酸生成 苯溴马隆 ：促进尿酸排泄 托匹司他 ：新型黄嘌呤氧化酶抑制剂 这些药物对大多数患者有效，但部分患者存在疗效不佳、不耐受或肝肾功能受限等问题。 抗炎止痛药 秋水仙碱 ：急性发作期常用，但治疗窗窄，容易出现腹泻等副作用 非甾体抗炎药（NSAIDs） ：如布洛芬、塞来昔布等，但有胃肠道和心血管风险 糖皮质激素 ：抗炎效果好，但长期使用有较多副作用 对于传统药物效果不好或不能耐受的患者，尤其是 难治性痛风 ，就需要新的治疗手段了。 三、降尿酸生物制剂：从源头 "溶解" 尿酸 培戈洛酶：把尿酸 "拆" 成无害物质 培戈洛酶是一种 聚乙二醇化重组尿酸氧化酶 。 它的作用机制很特别：人类体内缺乏尿酸氧化酶，不能进一步分解尿酸。而培戈洛酶可以把尿酸迅速分解为尿囊素。尿囊素溶解度高、容易排出体外，是一种无害物质。 打个比方：传统降尿酸药是 "关上水龙头" 减少尿酸生成，而培戈洛酶是 "加装净化器"，直接把已经存在的尿酸分解掉。 适用人群 ：常规降尿酸治疗无效或不能耐受的难治性痛风患者 给药方式 ：静脉输注 特点 ：降尿酸作用强，可快速溶解已形成的痛风石 注意事项 ：可能出现输液反应或过敏反应，需在专业医疗环境下使用；研究显示，与甲氨蝶呤等免疫调节剂联用可提高持续应答率 需要说明的是，培戈洛酶属于生物制剂，价格较高，目前主要用于难治性痛风，不是所有患者都需要使用。 四、抗炎生物制剂：精准阻断炎症 "开关" 痛风急性发作时，\\IL-1β（白细胞介素 - 1β）\\ 是关键的炎症因子。它就像一个 "警报器"。一被激活就会召集大量免疫细胞冲到关节里，引发剧烈炎症。 IL-1β 抑制剂的作用，就是把这个 "警报器" 关掉，从源头阻断炎症反应。 国内已获批的两款 IL-1β 单抗 1. 伏欣奇拜单抗（金蓓欣 ®） 2025 年 6 月获批上市，是国内首款用于痛风性关节炎急性发作的 IL-1β 抑制剂 全人源单抗，特异性结合并阻断 IL-1β 适用于传统抗炎药物禁忌、不耐受或效果不佳的患者 2. 安弗利奇塔单抗（益赛那 ®，SSGJ-613） 2026 年 8 月 20 日获国家药监局批准上市，由三生国健研发 国产第二款靶向 IL-1β 的痛风创新单抗 用于成人痛风性关节炎急性发作的治疗 海外已上市的 IL-1 通路抑制剂 卡那单抗（Canakinumab） ：抗 IL-1β 单抗，2023 年获美国 FDA 批准用于复发性急性痛风，是美国首个获批用于痛风发作治疗的生物制剂，目前尚未进入中国 阿那白滞素（Anakinra） ：IL-1 受体拮抗剂，临床使用时间较长，部分情况下超说明书使用 利纳西普（Rilonacept） ：IL-1 陷阱蛋白，可结合 IL-1 抗炎生物制剂的优势 起效快 ：直接阻断关键炎症因子，缓解急性发作 靶向性强 ：只作用于 IL-1 通路，不影响整个免疫系统 为传统药物不耐受的患者提供新选择 ：尤其是有胃肠道疾病、心血管疾病或肝肾功能不全的患者 需要注意的是，IL-1β 抑制剂主要用于 急性发作期的抗炎治疗 ，难以替代降尿酸治疗。控制血尿酸水平仍然是痛风长期管理的核心。 五、口服创新药物：不用打针的新选择 生物制剂虽然效果好，但需要注射给药，对一些患者来说不够方便。口服创新药物的研发也在推进。 新型口服降尿酸药 托匹司他 ：新型黄嘌呤氧化酶抑制剂，对氧化型和还原型黄嘌呤氧化酶均有抑制作用，降尿酸效果明确，在日本已上市多年 其他在研的口服降尿酸新药：包括新型 URAT1 抑制剂等，通过促进尿酸排泄发挥作用，部分尚在临床研究阶段 口服抗炎新药 针对痛风炎症通路的口服小分子药物也在研发中，部分尚在研究阶段 秋水仙碱的低剂量方案：研究显示低剂量秋水仙碱疗效与高剂量相当，但副作用明显减少，已被指南推荐 口服药物的优势是使用方便、患者依从性好，适合长期管理。但对于急性重度发作或难治性痛风，注射用生物制剂可能起效更快、作用更强。 六、双通路管理：既降尿酸又抗炎 2026 年痛风治疗的一个重要理念是 双通路管理 ： 降尿酸通路 ：通过别嘌醇、非布司他、苯溴马隆或培戈洛酶等，把血尿酸控制在目标范围，减少结晶形成 抗炎通路 ：通过秋水仙碱、NSAIDs、激素或 IL-1β 抑制剂等，控制急性炎症，减少发作频率 两条通路不是互相替代，而是互相配合。就像治理一条河。既要在上游植树造林减少泥沙（降尿酸），也要在下游疏浚河道防洪（抗炎）。 对于反复发作的痛风患者，医生通常会根据具体情况，制定个体化的联合治疗方案。 七、关于痛风治疗，这几个误区要避开 误区一：痛风发作时吃降尿酸药就行 急性发作期不建议自行加用降尿酸药，因为血尿酸快速波动可能加重炎症。发作期以抗炎止痛为主，降尿酸治疗通常在发作缓解后开始或调整。 误区二：不痛了就可以停药 痛风是慢性疾病，血尿酸长期达标是减少复发的关键。不痛不代表尿酸正常，不建议自行停药，需在医生指导下长期管理。 误区三：生物制剂是 "万能药"，人人都该用 生物制剂主要用于传统药物效果不佳或不耐受的难治性痛风，有明确的适用人群。大多数患者通过传统药物和生活方式干预就能有效控制。 误区四：只吃药不控制饮食 药物治疗很重要，但生活方式干预是基础。限制高嘌呤食物、减少饮酒、控制体重、多喝水，对痛风管理同样重要。 误区五：痛风只是关节痛，没什么大不了 长期高尿酸不仅损害关节，还可能影响肾脏（痛风性肾病、肾结石），并与心血管疾病、代谢综合征相关。需要重视并规范管理。 八、总结一下 2026 年痛风治疗的新进展，可以概括为： 降尿酸和抗炎双通路发力，生物制剂和口服药物各有优势 。 降尿酸方面，培戈洛酶等生物制剂为难治性痛风提供了新选择 抗炎方面，国内已有伏欣奇拜单抗、安弗利奇塔单抗两款 IL-1β 单抗获批，卡那单抗在海外上市 口服创新药物不断涌现，使用更方便 双通路管理理念强调个体化、综合治疗 对于痛风患者来说，目前仍建议在风湿免疫科医生指导下规范治疗，定期监测血尿酸，同时保持健康的生活方式。新疗法的出现，为反复发作和难治性痛风患者带来了更多希望。 互动讨论 ：你或身边的人有痛风的经历吗？目前是怎么管理的？对这些新疗法有什么期待？欢迎在评论区留言，咱们一起交流～ 全文核心 ：痛风管理需降尿酸 + 抗炎双通路；2026 年国内已有伏欣奇拜单抗、安弗利奇塔单抗两款 IL-1β 抗炎生物制剂获批，培戈洛酶用于难治性降尿酸，口服创新药也在推进；生物制剂适用于传统药物效果不佳者，多数患者传统药物 + 生活方式即可控制。 身体不适请及时就医，用药遵医嘱。

Prescription-strength combination of acetaminophen and ibuprofen offers non-opioid treatment option and easier access for patients with mild-to-moderate acute pain AUCKLAND, New Zealand, Sept. 8, 2026 /PRNewswire/ -- Today, AFT Pharmaceuticals announced the U.S. launch of Combogesic®, a new FDA Approved, Non-Opioid, prescription-strength combination of acetaminophen and ibuprofen developed for adult patients (over age 18) for the short-term management of mild-to-moderate acute pain. This adds the US to 66 countries around the world where this product is now available. In partnership with the Mark Cuban Cost Plus Marketplace, Combogesic brings together two of the world's most well-known pain relievers. Combogesic offers a clinically proven, FDA approved combination, providing healthcare professionals with another non-opioid treatment option for appropriate patients. For one of healthcare's most common experiences, pain management can still involve unnecessary complexity. Utilizing AFT Pharmaceuticals' Qiksolv® formulation technology, Combogesic combines prescription-strength acetaminophen and ibuprofen into a single tablet. Rather than requiring patients to coordinate multiple medicines and dosing schedules, Combogesic delivers both analgesics in one treatment. Clinical studies have demonstrated the effectiveness of Combogesic in the short-term management of mild-to-moderate acute pain. "Expectations for pain management have evolved, yet the options to treat have remained limited," said Hartley Atkinson, founder and managing director of AFT Pharmaceuticals. "Rather than inventing another molecule, we asked whether we could rethink how two of the world's most well-known pain medicines could work together in a single prescription-strength product. The result is a proven formulation that gives healthcare professionals another non-opioid treatment option for appropriate patients." That philosophy extends beyond the medicine itself. Through their partnership with the Mark Cuban Cost Plus Marketplace", AFT Pharmaceuticals is pairing pharmaceutical innovation with a world class pharmaceutical distribution model intended to improve patient health and making Combogesic accessible and affordable to patients across the United States. "We should all get excited to have more prescription, non-opioid options to combat pain" said Mark Cuban, founder of Mark Cuban Cost Plus Drug Company. "We started Mark Cuban Cost Plus Marketplace because every American should have access to safe, affordable medicines as an essential part of advancing healthcare. So ultimately patients benefit when new medications are paired with access and price transparency. That's exactly what this partnership is about. We're proud to help make Combogesic available to patients across the country." As pain management continues to evolve, healthcare professionals and patients are looking for treatment options that reflect the realities of modern care. Combogesic reflects AFT Pharmaceuticals' commitment to expanding non-opioid treatment options for appropriate patients. For more information, visit Combogesic.com. IMPORTANT SAFETY INFORMATION See full prescribing information for complete boxed warning. About AFT Pharmaceuticals AFT is a growing New Zealand-based multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories, which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs. Our business model is to develop and in-license products for our markets of Australia, New Zealand, Singapore, Malaysia, Hong Kong, USA, Canada, EU ex Ireland and UK, and to out-license our products to licensees and distributors in over 125 countries around the world. For more information about the company, visit our website About Mark Cuban Cost Plus Drugs The Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) aims to fundamentally change the way the pharmaceutical industry operates. As a public-benefit corporation, its social mission of improving public health is just as important as the bottom line. Cost Plus Drugs transparently charges a standard markup on every drug it sells. The costplusdrugs.com online pharmacy launched in January 2022 now carries over 2,300 prescription products, delivered by mail to thousands of happy customers every day. Customers can also go to participating retail pharmacies to receive Cost Plus Drugs pricing through the Team Cuban Card. Cost Plus Drugs is working with health plans, managed-care organizations, PBMs, and self-insured employers to bring these same savings to benefit plans nationwide. Learn more at . IMPORTANT SAFETY INFORMATION Continued… Contraindications patients with known hypersensitivity to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients. the setting of coronary artery bypass graft (CABG) surgery. Warnings and Precautions Hepatotoxicity. COMBOGESIC® contains acetaminophen and ibuprofen. Acetaminophen has been associated with cases of acute liver failure; the risk is higher in those with underlying liver disease and in those who ingest alcohol. Use in patients with hepatic impairment is not recommended. Elevations of ALT or AST have been reported in NSAID-treated patients. Cardiovascular Thrombotic Events. To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible. Gastrointestinal Bleeding, Ulceration, and Perforation. NSAIDs may cause serious and sometimes fatal GI adverse events at any time and without warning. Avoid use in patients at higher risk. In concomitant use with low-dose aspirin, monitor patients more closely for evidence of GI bleeding. Hypertension. NSAIDs can lead to onset of new hypertension or worsening of pre-existing hypertension, which may contribute to the increased incidence of CV events. Heart Failure and Edema. Avoid use in patients with severe heart failure unless benefits outweigh risk. Renal Toxicity and Hyperkalemia. Use in patients with renal impairment is not recommended. Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Increases in serum potassium concentration, including hyperkalemia, have been reported. Hypersensitivity and Anaphylactic Reactions. Hypersensitivity and anaphylaxis associated with ibuprofen and acetaminophen have been reported, including life-threatening anaphylaxis associated with acetaminophen. Exacerbation of Asthma Related to Aspirin Sensitivity. Patients with asthma may have intolerance to aspirin and other NSAIDs. Serious Skin Reactions. Acetaminophen or NSAIDs may cause serious skin reactions such as exfoliative dermatitis, acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), or fixed drug eruption (FDE), generalized bullous fixed drug eruption (GBFDE), which can be fatal and may occur without warning. Discontinue the use of COMBOGESIC® at the first appearance of skin rash or any other sign of hypersensitivity. Drug Rash with Eosinophilia and Systemic Symptoms (DRESS). DRESS that may be life-threatening or fatal has been reported in patients taking NSAIDs. Fetal Toxicity: Premature Closure of Fetal Ductus Arteriosus. Avoid use of COMBOGESIC® in pregnant women at about 30 weeks gestation and later. COMBOGESIC® increases the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age. Oligohydramnios/Neonatal Renal Impairment. Use of COMBOGESIC® at about 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. Hematologic Toxicity. Anemia has occurred in NSAID-treated patients and NSAID-treatment may increase the risk of bleeding events. Ophthalmological Effects. Blurred or diminished vision, scotomata, and/or changes in color vision have been reported with oral ibuprofen. Aseptic Meningitis. Aseptic meningitis with fever and coma has been observed in patients on oral ibuprofen. Masking of Inflammation and Fever. Activity of COMBOGESIC® in reducing inflammation, and possibly fever, may diminish signs of infections. Laboratory Monitoring. Monitor patients on long-term NSAID treatment with a CBC and a chemistry profile periodically. Adverse Reactions The most common adverse reactions (> 2%) are nausea, vomiting, headache, dizziness, somnolence, post-procedural hemorrhage, and swelling of the face. Drug Interactions Drugs That Interfere with Hemostasis. Ibuprofen and anticoagulants have a synergistic effect on bleeding. Concomitant use increases the risk of serious bleeding. Concomitant use of drugs that interfere with serotonin reuptake and an NSAID may increase the risk of bleeding. ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers. NSAIDs may diminish the antihypertensive effect of ACE inhibitors, ARBs, or Beta-Blockers. In the elderly, volume depleted, or those that have renal impairment, concomitant use with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure. Diuretics. NSAIDs can reduce the natriuretic effect of loop diuretics and thiazides in some patients. Digoxin. Concomitant use of ibuprofen with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. Lithium. NSAIDs produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. Methotrexate. Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity. Cyclosporine. Concomitant use of NSAIDs and cyclosporine may increase cyclosporine's nephrotoxicity. NSAIDS and Salicylates. Concomitant use with other NSAIDs or salicylates increases the risk of GI toxicity. Pemetrexed. Concomitant use of NSAIDs and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity. Indications and Usage COMBOGESIC® is indicated in adults (over age 18) for the short-term management of mild to moderate acute pain. To report an adverse event or product complaint, please contact us at [email protected] or call 01-248-631-4810. Adverse events may also be reported to the FDA directly at 1-800-FDA-1088 or . SOURCE AFT Pharmaceuticals 21% more press release views with Request a Demo